Increased matrix metalloproteinase 2 activity in the human internal mammary artery is associated with ageing, hypertension, diabetes and kidney dysfunction

被引:29
作者
Chung, A. W. [1 ]
Booth, A. D. [2 ,3 ]
Rose, C. [2 ,3 ]
Thompson, C. R.
Levin, A. [2 ,3 ]
van Breemen, C. [1 ]
机构
[1] Univ British Columbia, James Hogg iCAPTURE Ctr Cardiovasc & Pulmonary Re, Vancouver, BC V5Z 1M9, Canada
[2] Univ British Columbia, St Pauls Hosp, Div Nephrol, Vancouver, BC V5Z 1M9, Canada
[3] Univ British Columbia, St Pauls Hosp, Div Cardiol, Vancouver, BC V5Z 1M9, Canada
关键词
matrix metalloproteinase 2; internal mammary artery; diabetes; kidney function; hypertension;
D O I
10.1159/000119755
中图分类号
Q4 [生理学];
学科分类号
071003 ;
摘要
Dysregulation of matrix metalloproteinase (MMP)-2 in the vasculature has been suggested to be associated with increased prevalence of cardiovascular disease and renal injury. In this descriptive study, we hypothesized that arterial MMP-2 activity is elevated in the presence of cardiovascular risk factors such as diabetes, hypertension, smoking and ageing, and that it correlates with the degree of kidney function. MMP-2 activity in internal mammary arteries (n = 37) was measured using gelatinolytic zymography, and cutoffs were determined using sample-derived medians. Patient demographics and clinical data were analyzed, and the estimated glomerular filtration rate (eGFR) was calculated. High MMP-2 activity (1 60,000 units) was associated with age, hypertension and diabetes (p = 0.0034, 0.06 and 0.0034, respectively). Multivariate analysis showed that age and diabetes were independent predictors of high MMP-2 activity. There is a trend towards increased MMP-2 activity and reduced eGFR (p = 0.010). The current exploratory work describes that the activity of MMP-2 in the internal mammary artery is correlated with age, hypertension, diabetes and eGFR. It is the first report suggesting that MMP-2 in the arterial vasculature could be the possible mediator crucial in linking the progression of kidney function to cardiovascular disease. Copyright (C) 2008 S. Karger AG, Basel.
引用
收藏
页码:357 / 362
页数:6
相关论文
共 24 条
[1]   Specific changes in plasma concentrations of matrix metalloproteinase-2 and-9, TIMP-1 and TGF-β1 in patients with distinct types of primary glomerulonephritis [J].
Bauvois, Brigitte ;
Mothu, Nadya ;
Nguyen, Juliette ;
Nguyen-Khoa, Thao ;
Noel, Laure-Helene ;
Jungers, Paul .
NEPHROLOGY DIALYSIS TRANSPLANTATION, 2007, 22 (04) :1115-1122
[2]   Relationships between circulating matrix metalloproteinase-2 and-9 and renal function in patients with chronic kidney disease [J].
Chang, HR ;
Yang, SF ;
Li, ML ;
Lin, CC ;
Hsieh, YS ;
Lian, JD .
CLINICA CHIMICA ACTA, 2006, 366 (1-2) :243-248
[3]   Matrix metalloproteinase 2 and basement membrane integrity: a unifying mechanism for progressive renal injury [J].
Cheng, Sunfa ;
Pollock, Allan S. ;
Mahimkar, Rajeev ;
Olson, Jean L. ;
Lovett, David H. .
FASEB JOURNAL, 2006, 20 (11) :1898-+
[4]   Reduced expression of vascular endothelial growth factor paralleled with the increased angiostatin expression resulting from the upregulated activities of matrix metalloproteinase-2 and-9 in human type 2 diabetic arterial vasculature [J].
Chung, Ada W. Y. ;
Hsiang, York N. ;
Matzke, Lise A. ;
McManus, Bruce M. ;
van Breemen, Cornelis ;
Okon, Elena B. .
CIRCULATION RESEARCH, 2006, 99 (02) :140-148
[5]   Pressure distention compared with pharmacologic relaxation in vein grafting upregulatcs matrix metalloproteinase-2 and-9 [J].
Chung, AWY ;
Rauniyar, P ;
Luo, HL ;
Hsiang, YN ;
van Breemen, C ;
Okon, EB .
JOURNAL OF VASCULAR SURGERY, 2005, 42 (04) :747-756
[6]   Downregulation of vascular matrix metalloproteinase inducer and activator proteins in hypertensive patients [J].
Ergul, A ;
Portik-Dobos, V ;
Hutchinson, J ;
Franco, J ;
Anstadt, MP .
AMERICAN JOURNAL OF HYPERTENSION, 2004, 17 (09) :775-782
[7]   Matrix metalloproteinases in vascular remodeling and atherogenesis - The good, the bad, and the ugly [J].
Galis, ZS ;
Khatri, JJ .
CIRCULATION RESEARCH, 2002, 90 (03) :251-262
[8]   Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization [J].
Go, AS ;
Chertow, GM ;
Fan, DJ ;
McCulloch, CE ;
Hsu, CY .
NEW ENGLAND JOURNAL OF MEDICINE, 2004, 351 (13) :1296-1305
[9]   The potential of matrix metalloproteinase-2 as a marker of peritoneal injury, increased solute transport, or progression to encapsulating peritoneal sclerosis during peritoneal dialysis - a multicentre study in Japan [J].
Hirahara, Ichiro ;
Inoue, Makoto ;
Okuda, Kousuke ;
Ando, Yasuhiro ;
Muto, Shigeaki ;
Kusano, Eiji .
NEPHROLOGY DIALYSIS TRANSPLANTATION, 2007, 22 (02) :560-567
[10]   Matrix metalloproteinase expression in the coronary circulation induced by coronary angioplasty [J].
Hojo, Y ;
Ikeda, U ;
Katsuki, T ;
Mizuno, O ;
Fujikawa, H ;
Shimada, K .
ATHEROSCLEROSIS, 2002, 161 (01) :185-192